PCSK9 Inhibitors for Hypercholesterolemia
For adults with hypercholesterolemia whose LDL-C remains ≥70 mg/dL despite maximally tolerated statin therapy, add ezetimibe first; if LDL-C remains ≥70 mg/dL on statin plus ezetimibe, add a PCSK9 inhibitor (evolocumab or alirocumab). For statin-intolerant patients, use ezetimibe as first-line therapy, then add a PCSK9 inhibitor if LDL-C remains ≥70 mg/dL 1, 2.
Stepwise Algorithm for Biologic Therapy
Step 1: Maximize Statin Therapy
- Use high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) to achieve ≥50% LDL-C reduction 2, 1
- If intolerant, use maximum tolerated dose
Step 2: Add Ezetimibe
When to add: LDL-C ≥70 mg/dL on maximally tolerated statin 2, 1, 3
- Ezetimibe reduces LDL-C by an additional 20-25% 1
- This is a Class I recommendation (strongest evidence) for very high-risk patients 1
- Cost consideration: Ezetimibe is substantially less expensive than PCSK9 inhibitors and should always be tried first 2
Step 3: Add PCSK9 Inhibitor
When to add: LDL-C remains ≥70 mg/dL despite statin plus ezetimibe 2, 1, 3
Available PCSK9 inhibitors:
- Evolocumab: 140 mg subcutaneously every 2 weeks OR 420 mg monthly 1
- Alirocumab: Similar dosing schedule 2
- Inclisiran: 284 mg subcutaneously initially, at 3 months, then every 6 months (offers adherence advantage with twice-yearly dosing) 4
Expected LDL-C reduction: 55-75% when added to statin therapy 1, 5
Risk Stratification Determines Thresholds
The guidelines differ slightly on LDL-C thresholds based on cardiovascular risk:
Very High-Risk Patients (Secondary Prevention)
Definition: History of multiple major ASCVD events OR one major ASCVD event plus multiple high-risk conditions 2
- Target: LDL-C <55 mg/dL with ≥50% reduction from baseline 1
- Add ezetimibe: If LDL-C ≥70 mg/dL on statin (Class I) 2, 1
- Add PCSK9 inhibitor: If LDL-C ≥70 mg/dL on statin plus ezetimibe (Class I) 1
- Consider even lower target: LDL-C <40 mg/dL if recurrent event within 2 years on maximal therapy 1
High-Risk Patients (Primary Prevention with Risk Factors)
- Target: LDL-C <70 mg/dL 6
- Add ezetimibe: If LDL-C ≥70 mg/dL on statin 6
- Add PCSK9 inhibitor: If LDL-C ≥100 mg/dL on statin plus ezetimibe 6
Severe Primary Hypercholesterolemia (LDL-C ≥190 mg/dL)
- Add ezetimibe: If LDL-C remains ≥100 mg/dL on statin 2
- Add PCSK9 inhibitor: If LDL-C remains ≥100 mg/dL on statin plus ezetimibe, especially with familial hypercholesterolemia 2
Statin-Intolerant Patients
For patients who cannot tolerate any statin regimen:
- First-line: Ezetimibe 1
- Second-line: Add bempedoic acid if goal not achieved (Class I) 1
- Third-line: Add PCSK9 inhibitor if still not at goal 2, 1
Alternative oral option: Bempedoic acid provides liver-selective LDL-C lowering and showed cardiovascular event reduction in the CLEAR Outcomes trial for statin-intolerant patients 7, 4
Critical Implementation Considerations
Shared Decision-Making Required
The 2022 BMJ guideline emphasizes that benefits are modest (small absolute risk reductions in MI and stroke) and must be weighed against burdens 6:
- Injection requirements (except inclisiran's twice-yearly dosing)
- Cost (~$14,300/year for PCSK9 inhibitors at 2018 prices) 2, 3
- Long-term safety beyond 3 years remains uncertain 2
Cost-Effectiveness Concerns
- PCSK9 inhibitors have "low cost value" (>$150,000 per quality-adjusted life year) at mid-2018 list prices 2, 3
- Patient assistance programs and copay cards may reduce out-of-pocket costs 7
- Prior authorization barriers frequently delay or prevent access 4
Monitoring
- Check lipid panel 4-12 weeks after initiating or changing therapy 8, 9
- Reassess annually once stable 8
Common Pitfalls to Avoid
- Skipping ezetimibe: Always add ezetimibe before PCSK9 inhibitors—it's effective, oral, and far less expensive 2, 1
- Not maximizing statin dose first: Ensure truly maximally tolerated statin therapy before adding biologics 2
- Ignoring adherence barriers: Injectable therapies have lower real-world persistence; consider inclisiran for adherence-challenged patients 4
- Applying very high-risk thresholds to lower-risk patients: The strong recommendations for PCSK9 inhibitors apply specifically to very high-risk patients; evidence is weaker (Class IIb) for primary prevention 6